Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes

Peck, Amy R; Witkiewicz, Agnieszka K; Liu, Chengbao; Klimowicz, Alexander C; Stringer, Ginger A; Pequignot, Edward; Freydin, Boris; Yang, Ning; Ertel, Adam; Tran, Thai H; Girondo, Melanie A; Rosenberg, Anne L; Hooke, Jeffrey A; Kovatich, Albert J; Shriver, Craig D; Rimm, David L; Magliocco, Anthony M; Hyslop, Terry; Rui, Hallgeir

doi:10.1186/bcr3328

Table 1 Characteristics of patients in Materials III, IV, V, and VI

From: Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes

		Material III prognosis (n= 233)		Material IV prognosis (n= 291)		Material V antiestrogen (n= 75)		Material VI antiestrogen (n= 97)
		Number	%	Number	%	Number	%	Number	%
Center	Fox Chase	64	27	-	-	19	25	-	-
	Kaiser	79	34	-	-	35	47	-	-
	Univ of Miami	30	13	-	-	11	15	-	-
	Washington Univ	60	26	-	-	10	13	-	-
Race	Asian	1	0.4	0	0	1	1.3	-	-
	Black	16	7	3	1	6	8	-	-
	White	216	93	287	99	67	89	-	-
	Other	0	0	1	0.3	1	1.3	-	-
Age (years)	< 50	42	18	86	30	9	12	6	6
	≥50	191	82	205	70	66	88	91	94
Size (cm)	< 2	117	50	114	39	41	55	39	40
	≥2 to < 5	107	46	133	46	34	45	43	44
	≥5	9	4	33	11	0	0	11	11
	Missing	0	0	11	4	0	0	4	4
Grade	1	61	26	67	23	17	23	14	14
	2	104	45	137	47	45	60	47	48
	3	68	29	48	16	13	17	32	33
	Missing	0	0	39	13	0	0	4	4
ER status	Negative	44	19	97	33	1	1.3	11	11
	Positive	186	80	163	56	72	96	80	82
	Missing	3	1.3	31	11	2	3	6	6
PR status	Negative	65	28	103	35	9	12	-	-
	Positive	122	52	151	52	56	75	-	-
	Missing	46	20	37	13	10	13	-	-
ER/PR status	Negative	44	19	68	23	1	1.3	12	12
	Positive	178	76	192	66	72	96	83	86
	Missing	11	5	31	11	2	3	2	2
HER2 status	Negative	-	-	217	75	-	-	77	79
	Positive	-	-	33	11	-	-	13	13
	Missing	-	-	41	14	-	-	7	7
Nodal status	Negative	233	100	291	100	73	100	42	43
	Positive	0	0	0	0	0	0	42	43
	Missing	0	0	0	0	0	0	13	13
Chemotherapy	Untreated	233	100	-	-	75	100	97	100
	Treated	0	0	-	-	0	0	0	0
	Missing	0	0	-	-	0	0	0	0
Hormone therapy	Untreated	233	100	-	-	0	0	0	0
	Treated	0	0	-	-	75	100	97	100
Radiation therapy	Untreated	187	80	-	-	48	64	36	37
	Treated	46	20	-	-	27	36	59	61
	Missing	0	0	-	-	0	0	2	2
Stat5a status	Low	30	13	200	69	9	12	24	25
	High	193	83	39	13	64	85	47	48
	Missing	10	4	52	18	2	3	26	27
CSS events	Number	52	22	107	37	10	13	56	58
TTR events	Number	56	24	-	-	13	17	60	62
Evaluable subjects for multivariate	Number	218	94	190	65	73	97	55	57
		Mean (Range)		Mean (Range)		Mean (Range)		Mean (Range)
Stat5a score	-	32 (0-90)		653 (175-2,099)		34.1 (0-80)		1,949 (727-4,626)
Date of diagnosis	Year	1974-1990		1953-1980		1986-1996		1990-2000
Age at diagnosis	Years	62.3 (31-88)		57.3 (24-86)		64.6 (43-88)		69.8 (38-89)
Tumor size	cm	2.1 (0.6-7.5)		2.5 (0.4-11)		1.9 (0.5-4.5)		2.7 (0.4-11)
Follow-up	Months	126 (3-326)		160 (1-425)		117 (10-195)		41 (4-143)

ER, estrogen receptor; PR, progesterone receptor; SD, standard deviation.

Back to article page

ISSN: 1465-542X

Contact us

Submission enquiries: journalsubmissions@springernature.com

Breast Cancer Research

Contact us